GIST Support International - logo

GIST Support International - GIST In the News
GIST Imagery

ESMO: Tumor Shrinkage Doesn't Predict Response to Imatinib Therapy in Patients With Gastrointestinal Stromal Tumors

Posted by Administrator (admin) on Mar 13 2006
GIST In the News >>

By Charlene Laino


VIENNA, AUSTRIA -- November 4, 2004 -- Lack of progression is the most clinically significant predictor of a patient's response to imatinib in patients with gastrointestinal stromal tumours (GIST), a new analysis shows.

While clinicians traditionally use tumour shrinkage to assess the anticancer activity of a given therapy, the new study suggests that, at least in this instance, the paradigm does not fit, said co-investigator Stan N. Finkelstein, MD, a senior research scientist at Massachusetts Institute of Technology Sloan School of Management in Cambridge, Massachusetts, United States.

"If you have a patient with GIST on imatinib and the disease is not progressing, it is worth keeping therapy up -- even if you don't see tumour shrinkage on radiological scans," Dr. Finkelstein said. "Patients with so-called stable disease do just as well as those who have a partial or complete response."

Full Text at:

Last changed: Mar 13 2006 at 11:52 AM


back to top